MET and non-small cell lung carcinoma: Activating somatic missense mutations with a carcinogenic effect have also been described in the N-domain of MET in sporadic papillary renal carcinomas and non-small-cell lung cancer, although, unlike activating missense variants in the tyrosine kinase domain, they were ligand-dependent [26].